Loading…
Janux Therapeutics, Inc. is projected to rise to $18.15 by 2027, a +20% move from its current price of $15.17. JANX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $14.86 | $15.18 | $15.50 | +0.04% |
| Aug 3 | $14.73 | $15.18 | $15.65 | +0.08% |
| Aug 4 | $14.64 | $15.19 | $15.76 | +0.13% |
| Aug 5 | $14.56 | $15.20 | $15.86 | +0.17% |
| Aug 6 | $14.49 | $15.20 | $15.95 | +0.21% |
| Aug 7 | $14.43 | $15.21 | $16.03 | +0.25% |
| Aug 8 | $14.38 | $15.22 | $16.10 | +0.30% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $14.38 | $15.22 | $16.10 | +0.30% |
| Week 2 | $14.09 | $15.26 | $16.53 | +0.60% |
| Week 3 | $13.88 | $15.31 | $16.88 | +0.89% |
| Week 4 | $13.71 | $15.35 | $17.19 | +1.19% |
| Week 5 | $13.57 | $15.40 | $17.47 | +1.49% |
| Week 6 | $13.45 | $15.44 | $17.74 | +1.80% |
| Week 7 | $13.34 | $15.49 | $17.99 | +2.10% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Janux Therapeutics, Inc. is a clinical stage biopharmaceutical company that develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer.
The company's clinical candidates include JANX007, a PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases.
The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc.
was incorporated in 2017 and is headquartered in San Diego, California.
Janux Therapeutics, Inc. (JANX) is the asset. The current price is $15.33, with a market capitalization of $934.89M and a market rank of 2424.
The forecast provides a year-by-year view of min/avg/max prices and ROI. For 2026 the min is $12.18, the avg is $15.33, the max is $20.48 (ROI 0; sentiment NEUTRAL). For 2027 the min is $15.14, the avg is $18.57, the max is $23.87 (ROI 21.1; sentiment BULLISH).
From 2027 onward, the forecast is bullish, with the avg price rising to $23.13 in 2030, $58.86 in 2040, and $107.72 in 2050, corresponding to ROIs of 50.9%, 284%, and 602.7%, respectively.
A major floor 15.3% below — a decisive break under it would weaken the trend.
The nearest floor, 6.3% below — buyers have tended to step in here.
The nearest ceiling, 10.4% above — a clean break opens room to run.
A major ceiling 18.1% above — clearing it would confirm fresh momentum.
Key JANX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of JANX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $15.26 | Sell | $15.31 | Sell |
| MA 10 | $15.53 | Sell | $15.45 | Sell |
| MA 20 | $15.83 | Sell | $15.48 | Sell |
| MA 50 | $14.89 | Buy | $15.15 | Buy |
| MA 100 | $14.66 | Buy | $15.26 | Sell |
| MA 200 | $16.84 | Sell | $17.33 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.32 | Neutral |
| Stoch RSI (14) | 17.58 | Buy |
| CCI (20) | -105.40 | Sell |
| Williams %R (14) | -83.85 | Info |
| MACD (12,26,9) | -0.15 | Sell |
| ROC (12) | -5.36 | Sell |
| Bollinger %B (20,2) | 0.17 | Neutral |
| Stochastic %K (14) | 16.15 | Buy |
| TRIX (15) | 0.24 | Buy |
| Awesome (5,34) | -0.05 | Sell |
| Ultimate (7,14,28) | 42.19 | Neutral |
| Momentum (10) | -1.09 | Sell |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 15.09 | Buy |
| ADX (14) | 13.99 | Neutral |
| ATR (14) | 0.34 | Info |
The 30-day technical picture is NEUTRAL, with RSI(14) at 50. The 50-day simple moving average is $14.76 and the 200-day simple moving average is $17.12.
Support is at $13.15 and resistance at $16.75. The 30-day range runs from $13.39 to $17.55, and annualized volatility sits at 40%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $12.18 | $15.17 | $20.21 | 0% | Neutral | |
| $14.76 | $18.15 | $23.41 | +20% | Neutral | |
| $16.14 | $20.27 | $26.95 | +34% | Bullish | |
| $15.90 | $20.34 | $27.69 | +34% | Bullish | |
| $17.07 | $22.18 | $30.80 | +46% | Bullish | |
| $19.19 | $25.28 | $35.73 | +67% | Bullish | |
| $20.25 | $27.03 | $38.81 | +78% | Bullish | |
| $23.97 | $32.38 | $47.16 | +113% | Bullish | |
| $26.49 | $36.20 | $53.43 | +139% | Bullish | |
| $26.45 | $36.55 | $54.61 | +141% | Bullish | |
| $38.03 | $55.19 | $86.85 | +264% | Bullish | |
| $63.39 | $99.90 | $169.65 | +559% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $12.18 | $15.17 | $18.04 | +0.00% |
| September 2026 | $12.88 | $15.15 | $18.24 | -0.15% |
| October 2026 | $13.34 | $15.77 | $19.15 | +4.10% |
| November 2026 | $13.75 | $16.32 | $19.95 | +3.47% |
| December 2026 | $13.78 | $16.42 | $20.21 | +0.65% |
Click any year to see its month-by-month JANX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, JANX could reach as high as $20.21, with a base case around $15.17 and support toward $12.18 — roughly 0% from $15.17. Price action looks broadly range-bound.
Expect JANX to range from $14.76 to $23.41 through 2027. The $18.15 average target implies a +20% move from current prices. That is up +20% on the projected 2026 average. A consolidation phase looks the most probable path here.
The JANX price prediction for 2028 points to an average of $20.27 (low $16.14, high $26.95) — a potential gain of +34% on today's $15.17. Momentum favours further upside here.
In 2029, JANX is projected to trade between $15.90 and $27.69, averaging $20.34 — a potential gain of +34% from today's $15.17. That is up 0% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Janux Therapeutics, Inc.'s 2030 outlook centres on $22.18, within a $17.07 to $30.80 range. That is up +9% on the projected 2029 average. That marks a +46% change versus current levels. Momentum favours further upside here.
By 2031, JANX could reach as high as $35.73, with a base case around $25.28 and support toward $19.19 — roughly +67% from $15.17. Buyers look set to stay in control over this stretch.
Expect JANX to range from $20.25 to $38.81 through 2032. The $27.03 average target implies a +78% move from current prices. That is up +7% on the projected 2031 average. Momentum favours further upside here.
The JANX price prediction for 2033 points to an average of $32.38 (low $23.97, high $47.16) — a potential gain of +113% on today's $15.17. Buyers look set to stay in control over this stretch.
In 2034, JANX is projected to trade between $26.49 and $53.43, averaging $36.20 — a potential gain of +139% from today's $15.17. That is up +12% on the projected 2033 average. Momentum favours further upside here.
Janux Therapeutics, Inc.'s 2035 outlook centres on $36.55, within a $26.45 to $54.61 range. That is up +1% on the projected 2034 average. That marks a +141% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, JANX could reach as high as $86.85, with a base case around $55.19 and support toward $38.03 — roughly +264% from $15.17. Momentum favours further upside here.
Expect JANX to range from $63.39 to $169.65 through 2050. The $99.90 average target implies a +559% move from current prices. That is up +81% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in JANX today (≈ 65.919578 JANX) could be worth
$6,585.51
+$5,585.51 (+559%) by 2050 · US Dollar
Based on the average projected JANX price of $99.9 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in JANXwould be worth at today's price.
$1,000 invested in JANX on Jul 31, 2025 (≈ 41.640642 JANX) would be worth
$631.69
-$368.31 (-36.8%) today · 0.63× · US Dollar
Based on a JANX entry price of $24.01 vs. today's $15.17.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $15.33 | $989.56 | -1.0% |
| 1 month ago | $14.66 | $1,034.79 | +3.5% |
| 3 months ago | $14.34 | $1,057.88 | +5.8% |
| 6 months ago | $13.99 | $1,084.35 | +8.4% |
| 1 year ago | $24.01 | $631.69 | -36.8% |
| All time (5.0y) ago | $34.02 | $445.91 | -55.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our JANX forecast.
Our base-case forecast reaches $30.00 around 2033.
Implied market cap at $30.00: $1.83B
The multi-year forecast shows bullish sentiment across the longer horizon, with 2027 through 2050 labeled BULLISH.
Key forward-looking averages include a 2030 average price of $23.13 with a 50.9% ROI, a 2040 average price of $58.86 with a 284% ROI, and a 2050 average price of $107.72 with a 602.7% ROI.
These are estimates, not guarantees, and actual results could differ. The forecast implies a meaningful upward trajectory from the 2026 baseline, but subject to market conditions and other uncertainties.
Tap a question to reveal the answer.
2030 average price is $23.13 with a min of $17.89 and a max of $31.93; ROI 50.9%; sentiment BULLISH.
Forecast shows bullish sentiment from 2027 through 2050 with rising average prices (e.g., 2027 avg $18.57; 2028 avg $20.70; 2029 avg $20.93; 2030 avg $23.13); these are estimates, not guarantees.
The forecast max prices are $91.68 in 2040 and $180.67 in 2050, so reaching $50 is within the modeled range.
Current price is $15.33 and market capitalization is $934.89M.
Average price is $18.57 with a min of $15.14 and a max of $23.87; ROI 21.1%; sentiment BULLISH.
Janux Therapeutics, Inc. Community Discussion
0Share your Janux Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.